Journal Article

Expert panel curation of 31 genes in relation to limb girdle muscular dystrophy

Macalalad, Kelly, Bronicki, Lucas, Savarese, Marco, Cooper, Sandra T., Gorokhova, Svetlana, McNulty, Shannon, Kang, Peter B., Tasca, Giorgio, Weihl, Conrad C., Nunnery, Teagan, Palus, Brooke, Maiga, Alassane Baneye, Elnagheeb, Marwa, Johari, Mridul, Kesari, Akanchha, Spencer, Melissa J., Rufibach, Laura, Thaxton, Courtney, Niu, Zhiyv, Levy, Jennifer, Beckmann, Jacques S., Lek, Monkol, Kennedy, April, Clause, Amanda R., Straub, Volker, Owens, Emma, Flowers, May, Self, Autumn, Ganesh, Vijay S., Mohan, Shruthi

2024

Overview

Objective Limb girdle muscular dystrophies (LGMDs) are a group of genetically heterogeneous autosomal conditions with some degree of phenotypic homogeneity. LGMD is defined as having onset >2 years of age with progressive proximal weakness, elevated serum creatine kinase levels and dystrophic features on muscle biopsy. Advances in massively parallel sequencing have led to a surge in genes linked to LGMD. Methods The ClinGen Muscular Dystrophies and Myopathies gene curation expert panel (MDM GCEP, formerly Limb Girdle Muscular Dystrophy GCEP) convened to evaluate the strength of evidence supporting gene–disease relationships (GDR) using the ClinGen gene–disease clinical validity framework to evaluate 31 genes implicated in LGMD. Results The GDR was exclusively LGMD for 17 genes, whereas an additional 14 genes were related to a broader phenotype encompassing congenital weakness. Four genes (CAPN3, COL6A1, COL6A2, and COL6A3) were split into two separate disease entities, based on each displaying both dominant and recessive inheritance patterns, resulting in curation of 35 GDRs. Of these, 30 (86%) were classified as definitive, 4 (11%) as moderate, and 1 (3%) as limited. Two genes, POMGNT1 and DAG1, though definitively related to myopathy, currently have insufficient evidence to support a relationship specifically with LGMD. Interpretation The expert‐reviewed assertions on the clinical validity of genes implicated in LGMDs form an invaluable resource for clinicians and molecular geneticists. We encourage the global neuromuscular community to publish case‐level data that help clarify disputed or novel LGMD associations.

• Publisher: John Wiley & Sons, Inc,Wiley,John Wiley and Sons Inc
• Subject: Calpain / Classification / Collagen / Collagen Type VI - genetics / Congenital diseases / Data Curation / Genes / Genetics / Humans / Kinases / Life Sciences / Muscle Proteins - genetics / Muscular Dystrophies, Limb-Girdle - diagnosis / Muscular Dystrophies, Limb-Girdle - genetics / Muscular dystrophy / Phenotype / Validity